Navigation Links
Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
Date:11/11/2008

in lower risk populations studied in the EURIDIS(1), ADONIS and ERATO(2) trials. This analysis showed that dronedarone reduced the incidence of first AF recurrence by 25 percent in patients in sinus rhythm at study initiation (p<0.001), and the incidence of first electrical cardioversion by 31 percent (p<0.001), compared with placebo.

Dronedarone also decreased mean heart rate during atrial fibrillation to 78 beats per minute, compared with 87 for placebo (p<0.001). Fewer patients developed permanent atrial fibrillation during the study in the dronedarone group - 178 patients (7.7%) compared with 295 patients (12.7%) in the placebo arm (p<0.001). In these patients, the non-significant reduction of CV hospitalization or death was 26% lower for those receiving dronedarone (p=0.096). These results are consistent with the overall study results.

"This study demonstrates both significant rhythm and rate controlling properties of dronedarone in the ATHENA population, which consisted of higher-risk patients with atrial fibrillation," added Dr. Richard Page, Professor and Head of the Division of Cardiology at the University of Washington School of Medicine, Seattle, USA and a member of the steering committee of the ATHENA study. "It is intriguing that there was a trend toward reduction of the primary endpoint of cardiovascular hospitalization or death even in patients with permanent AF, suggesting that the benefit of dronedarone may not only be linked to arrhythmia control."

The most frequently reported adverse events of dronedarone vs. placebo in the ATHENA trial were gastrointestinal effects (26% vs. 22%), skin disorders (10% vs. 8%, mainly rash) and mild increase in blood creatinine (4.7% vs. 1%) due to inhibition of tubular secretion of creatinine in the kidneys. The mechanism of blood creatinine increase was well defined in a separate study of healthy volunteers and is not indicative of renal toxicity. In the ATHENA trial, compared to placebo, drone
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
2. ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
3. ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress
4. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
7. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
8. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
9. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
10. Risedronate Reduced Risk of Fracture Among Osteoporotic Postmenopausal Women with History of Hip Fracture
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution provider ... diagnostic imaging centers in China , ... of Directors declared a special cash dividend of US$0.30 ... ("ADS")) on the Company,s outstanding ordinary shares. The total ...
(Date:7/28/2014)... 28, 2014   Cardioxyl Pharmaceuticals, Inc. announced ... that CXL-1427, a novel potential treatment for acute decompensated ... The company has now initiated dosing of hospitalized patients ... trial designed to further evaluate the drug,s safety and ... The Phase I clinical trial evaluated the safety and ...
(Date:7/28/2014)... 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... 2014 Financial Results and Highlights Conference CallWhen:Monday, August 4 ... How:Live on the Internet. Simply log onto our ... during the live event, a replay of the webcast ... www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, INC. Isis ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... Technologies Inc., the leading developer of non-invasive electrocardiographic ... $7.5 million Series "C" financing.  The proceeds from ... commercial efforts related to its ECVUE ™ ... (Logo: http://photos.prnewswire.com/prnh/20110531/DC10432LOGO ) CardioInsight recently ...
...  MAKScientific, LLC, a privately held company focused on the ... that it has entered into an exclusive, worldwide option ... BIIB ) to develop and commercialize drug candidates for ... diseases. Under the agreement, Biogen Idec will ...
Cached Medicine Technology:CardioInsight Announces Closing of $7.5 Million Equity Financing 2
(Date:7/28/2014)... to accept the diagnosis "growing pains" when they complained ... involving 3,000 adolescents has now shown that the knee ... the study that one in three young people between ... pain in their knees. Seven percent of the adolescents ... knee," says physiotherapist and PhD Michael Skovdal Rathleff from ...
(Date:7/28/2014)... WASHINGTON, July 28, 2014A group of researchers in Taiwan ... able to detect an early complication of diabetes sooner, ... proves safe and effective in clinical trials, it may ... effective treatment of this complication, called diabetic autonomic neuropathy, ... and Type 2 diabetes. The condition progressively affects the ...
(Date:7/28/2014)... new study of the European project SOPHIE has ... policies and gender inequalities in health in Europe. ... policies (central and southern Europe) and countries with ... self-perceived health, i.e. women reported poorer health than ... Europe countries, where women present a 27% higher ...
(Date:7/28/2014)... Northridge, CA (PRWEB) July 28, 2014 ... a $100 coupon for new patients. Finding a new dentist ... anxiety or dental issues that have gone untreated and worry ... provider. Dr. Ariz specializes in patients with special concerns and ... patients feels comfortable and right at home. This special coupon ...
(Date:7/28/2014)... Australia (PRWEB) July 28, 2014 What ... a happier lifestyle can often be a struggle that ... channel, psychic and medium, Lynette Leckie-Clark provides simple how-to ... book “The Magic of You.” With inspiring spiritual affirmations ... you can find empowerment, confidence and motivation for everyday ...
Breaking Medicine News(10 mins):Health News:Many people never grow out of their growing pains 2Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Gender inequalities in health: A matter of policies 2Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:Be Empowered to Achieve Happiness from New Book "The Magic of You" 2
... up to Take Control of Health, Take off Pounds to ... Gain ... a year makes!,What a difference people can make when they join together ... Washington,D.C. to join Dr. Ian Smith, Patti LaBelle, Yolanda Adams, Michael Strahan,Steve ...
... a,Washington, D.C.-based research, evaluation and consulting organization,today released ... finds,low awareness and knowledge levels about HIV/AIDS, but ... important predictors for heightened,awareness., Some key findings ... -- Only 1 percent of respondents were ...
... April 2, 2008 The Richard B. and,Lynne V. ... the Institute,s Board of Directors. As a director, she ... "We are delighted to have Mary Cheney join ... of the Cheney family,actively involved in shaping the major ...
... Oaks,Development Group announced today the company has closed on ... behind St. David Medical Center in Austin,Texas. A 29,724-square-foot ... being converted to Oaks, unique tenant-ownership model., Oaks, ... limited liability,company (L.L.C.). Tenant partners split ownership interest of ...
... Sky,One Medical, Inc. (OTC Bulletin Board: CSKI) ("China Sky ... pharmaceutical,medicinal and diagnostic products in China, today announced record,financial ... December 31,2007., Fourth Quarter 2007 Highlights ... from the fourth quarter of ...
... stalled at just 9 percent, HARTFORD, Conn., April ... need to re-examine its value proposition to break,out of ... broader market,according to a new study by Conning Research ... sold primarily by specialist agents,to a niche market of ...
Cached Medicine News:Health News:50 Million Pound Challenge Marks 1st Anniversary - What a Difference a Year Makes! 2Health News:50 Million Pound Challenge Marks 1st Anniversary - What a Difference a Year Makes! 3Health News:50 Million Pound Challenge Marks 1st Anniversary - What a Difference a Year Makes! 4Health News:Education and Media Key to Improving HIV/AIDS Awareness and Knowledge Levels in Afghanistan, New InterMedia Report Says 2Health News:Education and Media Key to Improving HIV/AIDS Awareness and Knowledge Levels in Afghanistan, New InterMedia Report Says 3Health News:Mary Cheney Joins the Cheney Cardiovascular Institute Board of Directors 2Health News:Oaks Development Group Acquires Medical Office Building in Austin, Texas 2Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 2Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 3Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 4Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 5Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 6Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 7Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 8Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 9Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 10Health News:China Sky One Medical, Inc. Announces Record Fourth Quarter and Fiscal Year 2007 Results 11Health News:Conning Research: Long Term Care Insurance Industry Continues to Search for Broader Market 2
... 300 watt xenon Light ... Endoscopy shares your commitment to ... highest quality care available through ... of advanced surgical instruments and ...
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
The new X7000 light source is specifically tuned for the demanding requirements of Progressive Scan High Definition. The X7000 Lightsource uses a 300 Watt Xenon Elliptical Bulb for crystal clear illu...
... STORZ has brought arthroscopic shaver systems to ... the introduction of the Powershaver SL. Just ... the market leader in surgical endoscopy, the ... important and highly specialized field of arthroscopic ...
Medicine Products: